Paper42787250PubMed
Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.
Gu C and 3 others. Front Immunol, 2026.
Cite this record
ConductScience Library. Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study. Papers, record 42787250. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42787250
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article, Comparative Study, Research Support, Non-U.S. Gov't
- Revised in PubMed
- 2026-10-27
Source PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glomerulonephritis, IGA | Major topic |
| Glucocorticoids | Major topic |
| Humans | |
| Female | |
| Male | |
| Adult | |
| Retrospective Studies | |
| Treatment Outcome | |
| Glomerular Filtration Rate | |
| Middle Aged | |
| Remission Induction | |
| Proteinuria |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40975564 | KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). | Kidney Int | 2025 | https://conductscience.org/library/papers/40975564 | PubMed |
| 2 | 36270561 | Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. | Kidney Int | 2023 | https://conductscience.org/library/papers/36270561 | PubMed |
| 3 | 33309134 | IgA Nephropathy: An Interesting Autoimmune Kidney Disease. | Am J Med Sci | 2021 | https://conductscience.org/library/papers/33309134 | PubMed |
| 4 | 39291217 | Exploring Novel Adverse Events of Nefecon. | Kidney Int Rep | 2024 | https://conductscience.org/library/papers/39291217 | PubMed |
| 5 | 35579642 | Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. | JAMA | 2022 | https://conductscience.org/library/papers/35579642 | PubMed |
| 6 | 40678796 | Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide. | Clin Kidney J | 2025 | https://conductscience.org/library/papers/40678796 | PubMed |
| 7 | 40061933 | Targeted-release budesonide: A comprehensive review on its potential in IgA nephropathy. | Heliyon | 2025 | https://conductscience.org/library/papers/40061933 | PubMed |
| 8 | 39518760 | IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment. | J Clin Med | 2024 | https://conductscience.org/library/papers/39518760 | PubMed |
| 9 | 37591292 | Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37591292 | PubMed |
| 10 | 39232245 | The pathogenesis of IgA nephropathy and implications for treatment. | Nat Rev Nephrol | 2025 | https://conductscience.org/library/papers/39232245 | PubMed |
| 11 | 39211339 | Therapy of IgA nephropathy: time for a paradigm change. | Front Med (Lausanne) | 2024 | https://conductscience.org/library/papers/39211339 | PubMed |
| 12 | 21949093 | The pathophysiology of IgA nephropathy. | J Am Soc Nephrol | 2011 | https://conductscience.org/library/papers/21949093 | PubMed |
| 13 | 28159829 | IgA Nephropathy. | Clin J Am Soc Nephrol | 2017 | https://conductscience.org/library/papers/28159829 | PubMed |
| 14 | 37103889 | Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy. | Expert Rev Clin Immunol | 2023 | https://conductscience.org/library/papers/37103889 | PubMed |
| 15 | 18838301 | How host-bacterial interactions lead to IgA synthesis in the gut. | Trends Immunol | 2008 | https://conductscience.org/library/papers/18838301 | PubMed |
| 16 | 40235631 | eGFR slope modelling predicts long-term clinical benefit with nefecon in a real-world IgAN population. | Clin Kidney J | 2025 | https://conductscience.org/library/papers/40235631 | PubMed |
| 17 | 41727461 | Efficacy and safety of Nefecon in IgA nephropathy: real world clinical practice. | Front Immunol | 2026 | https://conductscience.org/library/papers/41727461 | PubMed |
| 18 | 41244638 | The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective. | Clin Kidney J | 2025 | https://conductscience.org/library/papers/41244638 | PubMed |
| 19 | 38036542 | IgA nephropathy. | Nat Rev Dis Primers | 2023 | https://conductscience.org/library/papers/38036542 | PubMed |
| 20 | 40828437 | Clinical risk assessment of serum creatinine abnormalities during vancomycin therapy: a retrospective study using machine learning models. | Int J Clin Pharm | 2025 | https://conductscience.org/library/papers/40828437 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42787250
GET https://conductscience.org/api/papers/v1/42787250/references?page=2